Rebecca Sutphen - The Cancer Letter

Is gastrectomy indicated?
A study recently published in JAMA suggests lower lifetime gastric cancer risk for CDH1 mutation carriers. Will this lead to changes in management recommendations?

A study recently published in JAMA sheds light on cancer risks associated with carrying germline CDH1 mutations, challenging previous, potentially inflated, lifetime cancer risk estimates.

September 06, 2024

Vol.50 No.33

By Rebecca Sutphen, Sue Friedman and Jon Florin

Clinical Trials & Tribulations

Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists

In May, the American Society of Clinical Oncology released guidelines on the use of germline genetic testing panels in concert with tumor testing for cancer patients.1

June 07, 2024

Vol.50 No.23

By Rebecca Sutphen

Rebecca Sutphen, MD

Is gastrectomy indicated?
A study recently published in JAMA suggests lower lifetime gastric cancer risk for CDH1 mutation carriers. Will this lead to changes in management recommendations?

Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists

Renew today!

Subscriber content

Rebecca Sutphen, MD

Is gastrectomy indicated?A study recently published in JAMA suggests lower lifetime gastric cancer risk for CDH1 mutation carriers. Will this lead to changes in management recommendations?

Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists

Is gastrectomy indicated?
A study recently published in JAMA suggests lower lifetime gastric cancer risk for CDH1 mutation carriers. Will this lead to changes in management recommendations?